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Abstract
 
The major histocompatibility complex (MHC) class II–associated invariant chain (Ii) regulates
intracellular trafficking and peptide loading of MHC class II molecules. Such loading occurs after
 
endosomal degradation of the invariant chain to a 
 
z
 
3-kD peptide termed CLIP (class II–associ-
ated invariant chain peptide). Cathepsins L and S have both been implicated in degradation of Ii
to CLIP in thymus and peripheral lymphoid organs, respectively. However, macrophages from
mice deficient in both cathepsins S and L can process Ii and load peptides onto MHC class II
dimers normally. Both processes are blocked by a cysteine protease inhibitor, indicating the in-
volvement of an additional Ii-processing enzyme(s). Comparison of cysteine proteases expressed
by macrophages with those found in splenocytes and dendritic cells revealed two enzymes ex-
pressed exclusively in macrophages, cathepsins Z and F. Recombinant cathepsin Z did not gen-
erate CLIP from Ii–MHC class II complexes, whereas cathepsin F was as efficient as cathepsin S
in CLIP generation. Inhibition of cathepsin F activity and MHC class II peptide loading by
macrophages exhibited similar specificity and activity profiles. These experiments show that
cathepsin F, in a subset of antigen presenting cells (APCs), can efficiently degrade Ii. Different
APCs can thus use distinct proteases to mediate MHC class II maturation and peptide loading.
Key words: cysteine protease • antigen presentation • protease inhibitor • proteolysis • antigen 
presenting cell
 
Introduction
 
The MHC class II–associated invariant chain (Ii)
 
1
 
 is a type
II transmembrane protein that binds to the peptide binding
groove of newly synthesized MHC class II 
 
a
 
/
 
b
 
 het-
erodimers, thus preventing their premature association
with endogenous polypeptides. Ii also regulates intracellular
trafficking of MHC class II dimers. The Ii NH
 
2
 
-terminal
cytoplasmic domain contains an endosomal targeting signal
that promotes Ii/MHC class II trafficking through the en-
dosomal compartments of APCs (1–4). Within endosomal/
lysosomal compartments, the Ii lumenal domain undergoes
stepwise proteolytic degradation to yield progressively
smaller fragments. The smallest fragment that contains both
the NH
 
2
 
-terminal endosomal targeting sequence and a
COOH-terminal extension through the MHC class II pep-
tide–binding groove has been termed Iip10. The Iip10
fragment is converted subsequently to CLIP (class II–asso-
ciated invariant chain peptide), a 
 
z
 
3-kD peptide that is ul-
timately exchanged for antigenic peptide in the final step of
peptide loading (5–9). Once free from endosomal reten-
tion, peptide-loaded MHC class II dimers move to the cell
surface. Thus, the timing and pattern of proteolysis of Ii
dictate the route of maturation of MHC class II molecules
and likely the antigenic peptides that are ultimately pre-
sented.
Degradation of Iip10 to CLIP is an important regulatory
step in the maturation of MHC class II dimers. First, only
two of the known acidic cathepsins (Cats) have been dem-
onstrated to degrade Iip10 to CLIP, Cats S and L (10–12).
Cat S is the major Ii-degrading enzyme of B cells and den-
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dritic cells. B cells and dendritic cells from mice deficient in
Cat S do not convert Ii to CLIP and also accumulate MHC
class II–Iip10 complexes within lysosomes (13). Mice defi-
cient in Cat L show Iip10 accumulation to some extent,
but only in the thymic cortex, suggesting that Cat L is im-
portant for generation of CLIP at this site (14). The ubiqui-
tous and abundant endosomal proteases Cats B and D do
not degrade Iip10 (10). Second, immature dendritic cells
express MHC class II molecules but accumulate these
dimers largely within lysosomes because Ii is not degraded
beyond Iip10. This accumulation has been attributed to in-
hibition of Cat S by intracellular cystatins (15). Maturation
of dendritic cells is accompanied by a reduction in cystatin
levels and rapid Cat S–dependent degradation of Iip10,
peptide loading, and surface expression of peptide–MHC
class II complexes. Thus, conversion of Iip10 to CLIP is a
key step in the proteolytic processing of Ii and is regulated
both by the pattern of cysteine protease expression and ex-
pression of their endogenous inhibitors.
Splenocytes from Cat S–deficient mice have defective
MHC class II peptide loading, and Cat S
 
2
 
/
 
2
 
 mice exhibit
defective Th1-type antibody responses. However, IgE and
pulmonary eosinophilic responses to antigen challenge in
these mice are normal (11). This dichotomy raises the pos-
sibility that additional mechanisms exist to promote peptide
loading and MHC class II antigen presentation in these
mice. Here we explore this possibility by examining MHC
class II maturation in mice deficient in both Cat S and L,
currently the only known proteases capable of efficiently
degrading Ii beyond Iip10 in vivo. Because lung and peri-
toneal macrophages of Cat S
 
2
 
/
 
2
 
L
 
2
 
/
 
2
 
 mice show normal
peptide loading, we searched for additional cysteine pro-
teases expressed preferentially in macrophages. We describe
the identification and Ii-degrading functions of two such
enzymes, Cats Z and F.
 
Materials and Methods
 
Materials and Antibodies. N
 
-morpholinurea-leucine-homophen-
ylalanine-vinylsulfone-phenyl (LHVS) and the cysteine protease
active site probe 
 
125
 
I–JPM565 were synthesized as described (16,
17) and further purified by HPLC. Recombinant human Cats S
and F were prepared as described (18, 19). Recombinant human
Cat B was purchased from Calbiochem Corp. N22 is a hamster
mAb against mouse MHC class II molecules (20) and was a gift of
Dr. R.M. Steinman (The Rockefeller University, New York,
New York). All chemical reagents were purchased from Sigma
Chemical Co. unless otherwise indicated. Cat L
 
2
 
/
 
2
 
 mice
(C57BL6/J129) were obtained from Zeneca Pharmaceuticals and
phenotyped by hair loss (14). Correlation between hair loss and
genotype was confirmed by Southern blot analysis using mouse
Cat L cDNA. Cat S
 
2
 
/
 
2
 
 mice (C57BL6/J129) were genotyped as
described (11) and bred with Cat L
 
2
 
/
 
2
 
 mice to generate mice de-
ficient in both Cats. Such mice, other than hair loss, appeared
healthy.
 
Mouse Immunization and IgE Measurement.
 
Cat S
 
1
 
/
 
1
 
 and Cat
S
 
2
 
/
 
2
 
 mice were immunized intraperitoneally with 8 
 
m
 
g of OVA
admixed with 1 mg of aluminum hydroxide (Goldline Labs.),
boosted with 8 
 
m
 
g of OVA 5 d later, and nebulized with 0.5%
 
OVA in PBS on day 12. On day 15, mice were killed for serum
collection and bronchioalveolar lavage. Lavage fluid eosinophils
were visualized by eosin and hematoxylin staining of cytospin
preparations. Total IgE levels in serum were measured by ELISA
as described previously (11). In some experiments, Cat S
 
2
 
/
 
2
 
 mice
were also injected intraperitoneally with LHVS (100 mg/kg body
weight) every 48 h starting 2 d before the OVA immunization to
the end of the protocol. Both lavage fluids and serum were again
collected.
 
Metabolic Labeling of Mouse Peritoneal Macrophages.
 
Cat S
 
1
 
/
 
1
 
,
Cat S
 
2
 
/
 
2
 
, and Cat S
 
2
 
/
 
2
 
L
 
2
 
/
 
2
 
 mice were injected with 1 ml of 3%
thioglycollate (Sigma Chemical Co.). After 72 h, peritoneal mac-
rophages were prepared by three washes with PBS containing 6
mM EDTA. The macrophages were cultured in RPMI (Media-
Tech) with 10% FBS, 2 mM 
 
l
 
-glutamine, 100 
 
m
 
g/ml penicillin/
streptomycin, and 100–500 U/ml of mouse IFN-
 
g
 
 (Endogen).
After overnight culture in the absence or presence of protease in-
hibitor LHVS (5–1,000 nM), cells were pulsed with 
 
35
 
S protein
labeling mix (New England Nuclear) for 1 h and chased with
RPMI (10% FBS) overnight in the absence and presence of pro-
tease inhibitors. Cells were then lysed in NP-40 lysis buffer (5
mM MgCl
 
2
 
, 0.5% NP-40, and 50 mM Tris-HCl, pH 7.4), and
the protein concentration was normalized to radioactivity of
trichloroacetic acid precipitates. Each cell lysate was immunopre-
cipitated with N22, boiled or nonboiled in nonreducing sample
buffer, and separated on 12% SDS-PAGE as previously described
(11). In comparison, mouse splenocytes were also isolated from
Cat S
 
1
 
/
 
1
 
, Cat S
 
2
 
/
 
2
 
, and Cat S
 
2
 
/
 
2
 
L
 
2
 
/
 
2
 
 mice for pulse, chase, and
N22 immunoprecipitation.
Mouse alveolar macrophages were harvested from lavage fluids
as previously described (21). In brief, mouse lung was washed re-
peatedly with 1 ml of PBS with 6 mM EDTA. Macrophages
were pelleted and cultured in RPMI with 10% FBS and mouse
IFN-
 
g
 
 (100–500 U/ml). Cells were pulsed, chased, and immu-
noprecipitated with N22 as described above.
 
Cloning and Expression of Mouse Cat F cDNA.
 
A probe based
on 300 bp of human Cat F cDNA (19) was used to screen a
mouse brain UNI-ZAP XR cDNA library (Stratagene Inc.).
Two 1.9-kb full length Cat F cDNAs were isolated and fully se-
quenced with T7-Sequenase according to the manufacturer (Am-
ersham). The 1.9-kb cDNA was subcloned into the XhoI and
NotI restriction sites of the pcDNA-I expression vector (Invitro-
gen Corp.). The expression construct was purified and transfected
into human embryonic kidney 293 cells with Lipofectamine as
recommended by the manufacturer (GIBCO BRL). The expres-
sion of mouse Cat F was visualized by both Western blotting
analysis with mouse Cat F polyclonal antibodies (discussed be-
low) and reaction with the cysteine protease active site probe
 
125
 
I–JPM565 (22).
 
Preparation of Mouse Cat F Polyclonal Antibodies.
 
Mouse Cat F
cDNA was digested with EcoRI and fused in frame with maltose
binding protein expression vector pMAL-c (New England Bio-
labs). The construct was transformed into DH5
 
a
 
, and fusion
protein expression was induced with 0.3 mM isopropyl-
 
b
 
-
 
d
 
-
thiogalactoside for 7 h to overnight. Fusion protein was then sep-
arated on 10% SDS-PAGE and purified as described previously
(23). The purified fusion protein was used as antigen to immu-
nize rabbits for generating polyclonal antisera (Charles River
Labs.).
 
Cloning and Expression of Mouse Cat Z.
 
Three partial EST-tag
sequences (AA116604, AA870150, and AI304158) were used to
design both 5
 
9
 
 end sense primer and 3
 
9 
 
end
 
 
 
antisense primer. The
full length cDNA was generated with reverse transcription PCR 
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using mouse lung total RNA and high fidelity Expander (Boeh-
ringer Mannheim) as previously described (22). The full length
1-kb mouse Cat Z cDNA was fully sequenced with ABI auto-
mated DNA Sequencer (model 377). PCR fragment was sub-
cloned into PCR-Script™ Amp Cloning vector (Stratagene Inc.).
The fragment was further released with XhoI and XbaI and sub-
cloned into pcDNA-I expression vector (Invitrogen Corp.). The
construct was also transfected into 293 cells as described above.
 
Northern Blot Analysis.
 
Mouse splenocyte, peritoneal mac-
rophage, and flt-3–stimulated dendritic cell total RNA was pre-
pared using guanidine isothiocyanate lysate/cesium chloride gra-
dient ultracentrifugation as described previously (22). 20 
 
m
 
g of
total RNA from each sample was separated on 1.2% agarose gel.
After blotting onto Zeta-Probe GT Genomic Tested Blotting
Membrane (Bio-Rad Labs.), the membrane was probed with
[
 
32
 
P]dCTP-labeled full length mouse Cat F, Z, and S cDNA us-
ing express hybridization buffer (Clontech). After washings with
2
 
3 
 
SSC, 2% SDS; 1
 
3
 
 SSC, 1% SDS; and 0.1
 
3
 
 SSC, 0.1% SDS,
the membrane was exposed to Kodak BioMax MR-2 film.
 
Cysteine Protease Active Site Labeling and Mouse Cat F Immuno-
precipitation.
 
Mouse peritoneal macrophages were incubated
overnight in the presence or absence of protease inhibitor LHVS
(5 nM, 1 
 
m
 
M) or IFN-
 
g
 
 (100–500 U/ml). Cells were collected
and lysed in lysis buffer (50 mM sodium acetate, 1 mM EDTA,
1% Triton X-100, pH 4.2) for 1 h on ice. Protein concentration
was determined using a Bio-Rad Dc Protein Assay kit. Equal
amounts of cell lysate from each treatment were labeled with
HPLC-purified 
 
125
 
I–JPM565 (17) for 1 h at 37
 
8
 
C and boiled for 5
min, followed by a 10-fold dilution with NP-40 lysis buffer.
Mouse Cat F polyclonal antiserum–coated protein A–agarose
beads were added, and the samples were incubated overnight at
4
 
8
 
C, followed by at least five washes with the washing buffer
containing 50 mM Tris-HCl, pH 7.4, 0.5% NP-40, 150 mM
NaCl, and 5 mM EDTA. Protein A–agarose beads were resus-
pended into 200 
 
m
 
l of 1
 
3
 
 reducing protein sample buffer, boiled,
and analyzed by 12% SDS-PAGE. One-tenth of the original la-
beled lysates were directly separated by 12% SDS-PAGE as a
control for the immunoprecipitation. Dried gels were exposed to
Kodak BioMax MR-2 film.
 
In Vitro Digestion of Ii with Recombinant Cats.
 
Cat S gene–tar-
geted mouse splenocytes were isolated as described (11). After in-
cubation with 20 nM Con B (Ajinomoto Co.) and 0.5 mCi/ml
of Express 
 
35
 
S Protein Labeling Mix (New England Nuclear) in
methionine/cysteine-free medium overnight, splenocytes were
lysed in NP-40 lysis buffer for 1 h on ice. Samples were pre-
cleared and immunoprecipitated with N22-coated protein A–aga-
rose beads, followed by another overnight incubation at 4
 
8
 
C as
described above. The protein A–agarose beads were washed with
washing buffer at least five times. The immunoprecipitated MHC
class II 
 
ab
 
–Ii complexes were digested with recombinant Cats in
20 
 
m
 
l of cysteine protease assay buffer containing 50 mM sodium
acetate, pH 4.2, 0.05% Triton X-100, 1 mM EDTA, 1 mM phe-
nylmethylsulfonyl fluoride, 5 
 
m
 
g/ml of pepstatin A, and 3 mM
dithiothreitol for 1 h at 37
 
8
 
C, followed by separation on 10–20%
tricine gel (Novex). The dried tricine gel was exposed to Kodak
BioMax MR-2 film.
 
Kinetic Assays.
 
Cat F enzyme assays were performed at a con-
stant enzyme concentration (1 nM) in 100 mM potassium phos-
phate buffer, pH 6.5, containing 2.5 mM dithioerythreitol and
2.5 mM EDTA. 
 
Z
 
-Leu-Arg-MCA (benzylcarbonyl-
 
l
 
-leucyl-
 
l
 
-
arginine 4-methylcoumarinyl-7-amide) was used as the substrate,
and its Cat F–catalyzed hydrolysis was measured at room temper-
ature using a Perkin-Elmer fluorimeter (excitation and emission
 
wavelengths were 380 and 450 nm, respectively). Cystatins were
dissolved in the reaction buffer and added to reaction mixtures.
Cystatins A and B were provided by Dr. I. Bjork (Uppsala Uni-
versity, Uppsala, Sweden), and cystatin C was provided by Dr.
M. Abrahamson (University of Lund, Lund, Sweden).
 
Determination of K
 
i
 
 Value.
 
Steady-state rates were deter-
mined at eight different concentrations of inhibitor (0–5 
 
m
 
M)
and three fixed concentrations of substrate (1, 2, and 5 
 
m
 
M). 
 
K
 
i
 
values were determined by Dixon plots (plots of 1/v versus [I]),
which gave three intersecting lines. All experiments were re-
peated twice, and the 
 
K
 
i
 
 values represent the mean values of the
six intersecting points.
 
Results
 
Cat S–deficient Mice Show Defective IgE Responses in the
Presence of LHVS.
 
Cat S–deficient mice mount IgE re-
sponses and develop pulmonary eosinophilia normally after
immunization and challenge with OVA (11). Cat S is not
required for a normal Th2-like immune response. How-
ever, when Cat S
 
2
 
/
 
2
 
 mice and wild-type mice were in-
jected with the cysteine protease inhibitor LHVS (100 mg/
kg) intraperitoneally every 48 h, the IgE response (Fig. 1)
and perivascular eosinophilic infiltration (not shown) in
lungs of OVA-immunized mice was totally abrogated.
These results are similar to those observed with C57BL6
mice injected with LHVS during immunization with OVA
(24) and raise the possibility that a cysteine protease(s) other
than Cat S is required for IgE responses and pulmonary in-
flammation in this model. This finding led us to explore
MHC class II processing and peptide loading in mice defi-
cient in the two known cysteine proteases implicated in
CLIP generation, Cats S and L (11, 12, 14).
 
MHC Class II Molecules from Macrophages of Cat S/L Dou-
ble Knockouts Load Peptide Normally.
 
To examine Ii pro-
cessing and MHC class II peptide loading in the absence of
known Ii-processing enzymes, mice deficient in Cats S and
L were created by cross-breeding the respective single
“knockouts.” Processing of Ii–MHC class II complexes in
Cat S
 
2
 
/
 
2
 
L
 
2
 
/
 
2
 
 mice was evaluated initially in splenocytes.
Figure 1. LHVS blocks IgE response in Cat S–deficient mice. Mouse
sera from Cat S2/2 mice, Cat S2/2 mice injected with LHVS, and their
wild-type siblings were used for total IgE ELISA. Cat S2/2 and Cat S1/1
mice have similar IgE responses to OVA immunization. However, LHVS
(100 mg/kg/48 h) completely blocks the IgE response in Cat S2/2 mice.1180 Cathepsin F and Invariant Chain Processing
Cells were pulsed and then chased for 5 h to allow process-
ing, and MHC class II heterodimers were immunoprecipi-
tated. Splenocytes from Cat S2/2L2/2 and Cat S2/2 mice
showed identical accumulation of Iip10 and were equally
defective in peptide loading (Fig. 2 A). This was expected,
because mouse splenocytes express little or no Cat L. How-
ever, alveolar macrophages from Cat S2/2L2/2 mice de-
graded Ii and loaded peptide identically to macrophages
from wild-type mice (Fig. 2 B), although a low amount of
Iip10 accumulation was sometimes found in Cat S2/2 or
Cat S2/2L2/2 mouse macrophages. When the amounts of
peptide–MHC complexes among the various samples were
normalized by densitometry to MHC class II a chain in the
boiled samples, instead of total radioactive protein, there
was again no difference in formation of a/b peptide com-
plexes among the various types of mice (not shown). Like
alveolar macrophages, peritoneal macrophages from Cat
S2/2L2/2 mice were found to process Ii and present anti-
gen normally (Fig. 2 C). Thus, macrophages either have a
mechanism of exchanging larger fragments of Ii for peptide
that is distinct from splenocytes, or these cells express addi-
tional Ii processing enzyme(s) capable of generating CLIP.
We examined the importance of Ii processing for pep-
tide loading in macrophages by exposing Cat S2/2L2/2
peritoneal macrophages to either low or high doses of the
Cat S inhibitor LHVS. Prior studies showed that LHVS is
selective for Cat S at low concentrations (,10 nM),
whereas at higher concentrations additional cysteine pro-
teases are inhibited (16, 25). In the presence of LHVS (5
nM), Cat S2/2L2/2 macrophages process MHC class II–Ii
as effectively as controls (Fig. 2 C), consistent with the ob-
servation that macrophages from Cat S–deficient mice
have unimpaired Ii processing and peptide loading. Mac-
rophages cultured in 1 mM LHVS showed delayed Ii pro-
cessing (accumulation of Iip10) and peptide loading remi-
niscent of that seen in splenocytes from Cat S2/2 or Cat
S2/2L2/2mice. Thus, an additional cysteine protease(s) in
macrophages might substitute for Cat S in these cells.
Identification of Cysteine Proteases Expressed Preferentially in
Macrophages. We next compared the set of cysteine pro-
teases expressed by macrophages, B cells, and dendritic
cells. EST databases were screened for murine cysteine
protease cDNAs as a source of DNA probes. Sequences
were obtained for murine Cats O, W, K, Z, and F in addi-
tion to the major Cats H, B, L, and S. PCRs of reverse-
transcribed mRNA and Northern blot analyses were used
to compare the expression of these enzymes in macro-
phages, B cells, and dendritic cells. Cat W and K mRNA
was not seen in these cells, consistent with prior reports (26,
27). Low levels of Cat O were found in both B cells and
macrophages. Because this enzyme was comparable in
both cell types, Cat O was not further studied. Two en-
zymes, Cat Z and Cat F, were found to be expressed in
macrophages but not splenocytes or dendritic cells by
Northern blot analysis (Fig. 3 A). Comparison of mRNA
levels of Cats Z and F with levels of Cat S in macrophages
shows the relative level of Cat S to be considerably higher.
Whereas Cat S mRNA is also evident in splenocytes and
dendritic cells, longer exposure of the Northern blot
shown in Fig. 3 A did not reveal a signal for either Cat F
or Z mRNA in these cell types (not shown). Also unlike
macrophages, PCR amplification of reverse-transcribed
RNA failed to reveal Cats Z and F in splenocytes. Cats Z
and F were therefore characterized in more detail.
Full length cDNAs encoding murine Cats Z and F were
obtained as described in Materials and Methods. Compari-
son of the predicted amino acid sequences of human and
murine Cats reveals extensive homologies (78% for Cat F
and 79% for Cat Z). Cat Z has Cat B–like sequences with
a predicted loop structure between the active site cysteine
at amino acid residue 94 and the active site asparagine at
amino acid residue 264 (reference 28; Fig. 3 B). Interest-
Figure 2. MHC class II from Cat S2/2L2/2 mice load peptide normally. (A) Mouse splenocytes from wild-type, Cat S2/2, and Cat S2/2L2/2 mice
were pulsed for 1 h and chased overnight. Macrophages were then lysed in NP-40 lysis buffer, followed by immunoprecipitation with N22. The precip-
itates were either boiled (B) or nonboiled (NB) before separation on 12% SDS-PAGE. (B) Mouse alveolar macrophages were metabolically labeled and
immunoprecipitated with N22 and separated on 12% SDS-PAGE as splenocytes as in A. (C) Mouse peritoneal macrophages from Cat S2/2L2/2 were in-
cubated in LHVS (0 or 5 nM or 1 mM) overnight, followed by 1 h of pulse and overnight chase. Cells were then lysed, immunoprecipitated with N22,
and separated on 12% SDS-PAGE.1181 Shi et al.
ingly, the dihistidines found in the “occluding loop” of
Cat B appear to be replaced by asparagines in Cat Z (Fig. 3
B). Whether there is a true occluding loop in Cat Z re-
mains to be determined. Notably, the Cat Z sequence has
also been reported as Cat X in separate reports (29, 30).
Murine Cat F is also highly homologous to the previ-
ously reported human enzyme (19, 31, 32). As recently re-
ported for the full length human enzyme, murine Cat F
has an extended pro region with a cystatin-like sequence
near the NH2 terminus (Fig. 3 C). This characteristic ap-
pears unique to Cat F and is a feature conserved between
the human and murine enzymes (31). Whether this se-
quence has cystatin-like protease inhibitor activity also re-
mains to be determined.
Inhibitor Profiles of Recombinant Cat F and Z. An en-
zyme substituting for Cat S in APC Ii processing should be
sensitive to inhibition by high concentrations of LHVS.
Therefore, we tested the sensitivity of Cats F and Z to in-
creasing concentrations of LHVS. To conduct these stud-
ies, we used a probe based on the epoxide E-64, a class-
specific inhibitor of cysteine (17, 22). This inhibitor,
JPM565, was iodinated, and the sensitivity of human Cats
F and Z to LHVS was determined by competition of ac-
tive-site labeling by 125I–JPM565. Recombinant Cat F was
sensitive to LHVS but less so than Cat S. Inhibition is evi-
dent at 10–20 nM and virtually complete at 50 nM, mak-
ing the enzyme z10–50-fold less sensitive to LHVS than
Cat S (Fig. 4, left). In contrast to Cat F, mouse Cat Z ex-
pressed in 293 cells can be inhibited by 20 mM of E64 but
not 1 mM LHVS (Fig. 4, right). This observation indicates
Cat Z is an unlikely candidate to account for LHVS-sensi-
tive Ii processing observed in Cat S/L–deficient macro-
phages (Fig. 2). These findings are therefore consistent with
Cat F being a target enzyme for these inhibitors.
In additional experiments using recombinant human Cat
F and inhibitors of the cystatin family, hydrolysis of the
colorimetric substrate, Z-Leu-Arg-MCA by Cat F was
found to be markedly inhibited by cystatin C (Ki 5 0.532 6
0.1991 nM). The purified enzyme was much less sensi-
tive to cystatin A (Ki 5 6.645 6 0.862 nM) and cystatin B
(Ki 5 9.156 6 1.287 nM). These findings are in agreement
with the overall sequence similarity between Cats S and F
and imply an “open” substrate-binding cleft for Cat F, in
line with its marked endoproteolytic activity (19). In con-
trast, recent observations suggest that human Cat Z confers
stricter carboxypeptidase activity than Cat B. No endopep-
tidase activity was found with this exopeptidase, and no in-
hibition by cystatin C was detected even up to a concen-
tration of 4 mM of inhibitor (33). Because Cat F, and not
Cat Z, displayed the correct inhibitory profile with LHVS,
we focused on the expression of this enzyme in murine
macrophages.
Expression of Cat F in Murine Macrophages. Polyclonal
antibodies were raised against a fusion protein comprised
of the maltose-binding protein and a fraction of the mouse
Cat F coding sequence (from Glu221 to Asn462). These
antibodies were used to explore expression of Cat F in
Figure 3. Isolation and expression of mouse Cats F and Z. (A) North-
ern blot analysis. Total RNA (20 mg/each) from mouse splenocytes,
peritoneal macrophages, and flt-3–stimulated dendritic cells were sepa-
rated on 1.2% agarose gel, blotted onto a nylon filter, and probed with
full length mouse Cat F, Z, and S cDNAs. RNA loading control is
shown by rRNAs (top panel). Both Cats F and Z can be detected from
macrophages but not splenocytes or dendritic cells. In contrast, Cat S
transcripts can be detected in all three cell types. (B) Amino acid se-
quence of mouse Cat Z. The active site amino acids are indicated with
asterisks (*), and the potential sites for glycosylation are double under-
lined. Arrowheads indicate the potential cleavage sites of signal peptide
and pro region of Cat Z. (C) Amino acid sequence of mouse Cat F. Ar-
rowheads indicate the signal peptide and pro region cleavage sites. Three
active site amino acids (Cys, His, and Asn) are indicated by asterisks (*),
and three potential glycosylation sites are double underlined. The under-
lined region is the potential cystatin-like domain (32).
Figure 4. Cat F, but not Cat Z, fits the LHVS-inhibitable protease
profile of macrophages. Recombinant Cat F (5 nM) was labeled with
125I–JPM565 in the presence or absence of LHVS at the indicated con-
centrations for 1 h at 378C in pH 4.2 assay buffer with 3 mM dithiothrei-
tol (DTT) and then separated on 12% SDS-PAGE (left). Cat Z–trans-
fected 293 cells were lysed in lysis buffer, pH 4.2, and 100 mg of protein
was incubated with 125I–JPM565 in the presence of 3 mM DTT and in-
hibitors and separated on 12% SDS-PAGE (right).1182 Cathepsin F and Invariant Chain Processing
macrophages and splenocytes. The cysteine protease in-
hibitor 125I-JPM565 was added to equal amounts of cell
lysates, normalized for protein concentration, from mac-
rophages and splenocytes. The lysates were then immuno-
precipitated with anti–Cat F antibodies, and the precipi-
tates were analyzed by SDS-PAGE and autoradiography to
reveal active enzyme. Active site–labeled Cat F, migrating
as a z31–33 kD protein, was recovered from lysates of
macrophages but not splenocytes (Fig. 5 A). Notably,
when cell lysates were boiled for 5 min before immuno-
precipitation, the Cat F antibodies cross-reacted with and
immunoprecipitated Cat S, seen as the lower band in the
macrophage lane of Fig. 5 A. This was confirmed by per-
forming immunoprecipitations with the Cat F antibody in
Cat S–deficient mice (Fig. 5 C) as well as Cat S–transfected
293 cell lysates (data not shown).
To further determine whether low levels of Cat F are
expressed in splenocytes, 125I–JPM565-labeled Cat F was
immunoprecipitated from both splenocyte and macro-
phage lysates under conditions in which the splenocyte lysate
contained 10-fold greater protein content than the mac-
rophage lysate. This experiment was conducted without
preboiling of lysates, which clearly diminishes Cat S cross-
reactivity. Again, no Cat F signal can be detected from
splenocytes (Fig. 5 B). However, a sequential Cat S immu-
noprecipitation revealed Cat S expression in both spleno-
cytes and macrophages (Fig. 5 B). This is consistent with
the results of Northern blot analyses (Fig. 3).
As judged by 25I–JPM565 labeling, activity of Cat F was
blocked by 1 mM LHVS but not by a low dose of LHVS
(5 nM; Fig. 5 C). Because Cat F migrates with a molecular
mass similar to that of Cat B, we tested the possibility that
Cat F polyclonal antibodies cross-react with Cat B. Cat
B–deficient macrophages were labeled and immunoprecip-
itated with Cat F antibodies. Active Cat F was again ob-
served (Fig. 5 C). In addition, the antibody specificity was
also confirmed using Cat F–transfected 293 cell lysates. No
active cysteine proteases were revealed by this antibody in
sham-transfected cells nor in cells transfected with empty
vector (pcDNA-I; Invitrogen Corp.; Fig. 5 C). We con-
clude that the 31–33-kD active Cat F is expressed in mac-
rophages and not B cells.
Cat F Degrades Iip10 and Generates CLIP. Recombi-
nant enzymes were used to test the ability of Cats Z or F to
degrade Ii to CLIP. The amounts of active enzyme were
determined by active site titration as described (10). Com-
plexes of full length Ii and MHC class II dimers were ob-
tained by immunoprecipitation of metabolically labeled
splenocytes in the presence of Con B. Con B inhibits en-
dosomal ATPase, which disrupts the normal pH of these
compartments and results in a blockade of Ii processing.
Immunoprecipitated complexes were resuspended at acidic
pH (pH 4.2) and exposed to various amounts of recombi-
nant Cats as indicated in Fig. 6 A. After 1 h at 378C, the
reactions were stopped in SDS sample buffer, and the reac-
tion products were separated by SDS-PAGE and visualized
by autoradiography. The ability of these cysteine proteases
to degrade Iip10 was quantified by densitometry and nor-
malized to that seen with 5 nM recombinant Cat S (Fig. 6
B). As reported previously, compared with Cat S, Cat B
had no activity as an Ii-degrading protease (10). Murine
Cat Z, expressed in 293 cells, did not degrade Iip10 at any
concentration tested (Fig. 6 B). In contrast, human Cat F
was found to be as or more active than Cat S in Iip10 deg-
radation and CLIP formation (Fig. 6). Lysates of 293 cells
expressing murine Cat F also degraded Iip10, resulting in
CLIP formation (Fig. 6 B), whereas cells expressing mu-
rine Cat Z had no activity in this assay.
Figure 5. Cat F is expressed in macrophages and not splenocytes. (A) Equal amounts, normalized to protein content, of mouse peritoneal macro-
phages, splenocytes, and Cat F–transfected 293 cell lysates were labeled with 125I–JPM565, preboiled for 5 min, and immunoprecipitated with mouse Cat
F antibodies. The precipitates were separated on 12% SDS-PAGE. Cat F is not detected in splenocytes, whereas macrophages showed the 30–31-kD ac-
tive Cat F that was also present in Cat F–transfected 293 cells. (B) Splenocyte lysates containing 10-fold greater protein content than macrophages were
directly immunoprecipitated with Cat F antibodies without preboiling. Cat F can only be detected in macrophages and not splenocytes. The sequential
lysates were then boiled and further immunoprecipitated with Cat S antibodies to reveal Cat S expression in both types of cells. (C) Peritoneal macro-
phages from wild-type, Cat B2/2, and Cat S2/2 mice were incubated with or without LHVS (5 nM, 1 mM) overnight. The cells were lysed and protein
concentrations normalized. Equal amounts of protein from each sample were labeled with 125I–JPM565 and precipitated with Cat F polyclonal antisera.
Cat F activity was completely inhibited in cells incubated with 1 mM but not 5 nM LHVS. Immunoprecipitations of 125I–JPM565-labeled lysates of
macrophages from Cat S2/2 and Cat B2/2 mice indicate that the anti–Cat F antibodies cross-react with Cat S but not Cat B when boiled before immu-
noprecipitation. The size of mouse Cat F and the specificity of Cat F antibodies was also examined with Cat F–transfected 293 cell lysate and empty
vector– or sham-transfected 293 cell lysate.1183 Shi et al.
Discussion
Proteolytic processing of Ii is a critical determinant of
the timing and location of MHC class II peptide loading.
Although a number of proteases have been implicated in
progressive COOH-terminal cleavages of Ii to produce
Iip10, only a limited number of cysteine proteases, i.e.,
Cats S and L, appear capable of degrading Iip10 to generate
CLIP. We have identified an additional protease capable of
cleaving Iip10 to form CLIP: Cat F. Our data support the
conclusion that Cat F is a relevant protease in APC Iip10
processing. First, purified Cat F is at least as potent as Cat S
in Ii processing and CLIP formation (Fig. 6). Second, mac-
rophages deficient in Cats S and L process Ii and load pep-
tides onto MHC class II heterodimers normally (Fig. 2).
Nonetheless, Iip10 processing and peptide loading in these
cells remains sensitive to high concentrations of the cys-
teine protease inhibitor LHVS. Concentrations of LHVS
that result in abrogation of MHC class II a/b–peptide
SDS-stable complexes in macrophages (Fig. 2 B) also in-
hibit Cat F (Figs. 4 and 5 B), consistent with Cat F being
the protease responsible for Ii processing in the absence of
Cats S and L. Finally, macrophages express active Cat F.
Nonetheless, we cannot exclude the possibility that as yet
unknown additional cysteine proteases contribute to Iip10
processing in macrophages. Our data are consistent with
the notion that in macrophages, Cat F substitutes for and
potentially complements the function of Cat S in Iip10
processing. If so, manipulation of Iip10 processing and
MHC class II maturation by APCs in vivo may require an
inhibitor that attacks Cats F, L, and S. From the viewpoint
of Ii processing, these three enzymes appear to form a dis-
tinct subfamily of papain-type cysteine proteases.
Professional APCs are functionally heterogeneous but
have been clarified on the basis of distinct surface markers
and morphology into lymphoid- and myeloid-like den-
dritic cells, B cells, and macrophages. Recent evidence in-
dicates that flt-3 ligand promotes development of lym-
phoid-type dendritic cells, whereas GM-CSF promotes
development of predominantly myeloid-type dendritic
cells (34). B cells are functionally distinct from dendritic
cells in that they can use their surface Ig to capture and
process low levels of extracellular antigens. Macrophages
also present antigen efficiently in the context of inflamma-
tion (35–39). Although all types of APCs appear to express
Cat S, only macrophages express Cat F, whereas this en-
zyme is not detected in B cells or flt-3–stimulated murine
dendritic cells (Figs. 2 A and 5 A). The different pH pro-
files of Cats F and S allow the possibility that these enzymes
may function in distinct antigen processing compartments.
The pH optimum of Cat F favors its main site to be the ly-
sosome (19), whereas Cat S activity is present throughout
the endosomal/lysosomal pathways (13). The trafficking of
endogenous Cat inhibitors such as cystatin C may also fa-
vor, at least under some conditions, one enzyme over the
other in Iip10 processing. The true functional importance
of the finding of a second Iip10 processing enzyme in
APCs will require gene deletion and analysis of mice with
selective loss of Cat F.
The use of cysteine protease inhibitors in vivo has re-
cently emerged as a strategy to regulate immune responses
and the life cycle of certain parasites (40, 41). For example,
mice infected with Leishmaniasis major showed a shift of
CD41 T cell differentiation from Th2 to Th1 when mice
were treated with the Cat B inhibitor CA074 (42). IgE re-
sponses and pulmonary eosinophilia in mice immunized
with OVA are blocked by high concentrations of LHVS
(24). That this blockade cannot be explained by simple in-
hibition of Cat S is now clear given the fact that IgE re-
sponses in this OVA model are normal in Cat S–deficient
mice (Fig. 1). Th2-type T cell responses are still impaired
in LHVS-treated, Cat S–deficient mice. The identification
of Cat F as an LHVS-inhibitable protease (Fig. 4) fully
competent to process Ii-p10 and generate CLIP (Fig. 6)
may explain the normal Th2-type immune responses in
these mice. Stimulated lung macrophages could thus play a
more prominent role in antigen presentation than is cur-
rently believed. Further experiments are required to estab-
lish whether other populations of APCs within lungs ex-
press Cat F or if indeed lung macrophages, at least in the
setting of airway inflammation, become fully competent
and important for antibody responses to antigens that access
the immune system by this route.
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Figure 6. Cat F, but not Cat Z, degrades Iip10 from MHC class II–
Iip10 complexes, generating MHC class II–CLIP. (A) N22 immunopre-
cipitates from metabolically radiolabeled Cat S2/2 mouse splenocytes
treated with Con B (20 nM) were digested with either purified recombi-
nant human Cat F or purified recombinant human Cat S at the indicated
concentrations in assay buffer, pH 4.2, for 1 h at 378C. The digested
products were separated on 10–20% Tricine gel (Novex). (B) N22 immu-
noprecipitates were digested with 5 nM (as determined by cysteine pro-
tease active site titration; reference 10) of purified recombinant human
Cat F–, S–, and B– or mouse Cat F– and Z–transfected 293 cell lysates
and analyzed on a 10–20% Tricine gel. The Cat F and Z activity from cell
lysate was examined with 125I–JPM565 active site labeling. Densitometry
analysis was used to quantitate the Iip10 digestion products of each Cat.
CLIP-forming activities of recombinant Cat S and B are shown relative to
Cat F (as 100%). Also, Cat Z–transfected 293 cell lysate CLIP-forming
activity is shown relative to Cat F–transfected 293 cell lysate (as 100%).1184 Cathepsin F and Invariant Chain Processing
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